Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants - Oral Formulation III

NCT06097390 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06097390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06097390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants - Oral Formulation III
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
September 28, 2023
Completion date
March 27, 2024
Enrollment
121 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants